<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00747305</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000612590</org_study_id>
    <secondary_id>MUSC-101219</secondary_id>
    <nct_id>NCT00747305</nct_id>
  </id_info>
  <brief_title>Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery</brief_title>
  <official_title>Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harry Drabkin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before&#xD;
      surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be&#xD;
      removed. Giving it after surgery may kill any tumor cells that remain after surgery.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well sunitinib works when given before and after&#xD;
      surgery in treating patients with metastatic kidney cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To describe the gene expression of VEGF and non-VEGF angiogenic growth factor genes in&#xD;
           kidney cancer specimens from patients with metastatic renal cell carcinoma treated with&#xD;
           sunitinib malate.&#xD;
&#xD;
        -  To describe the association between quantitative gene expression levels of VEGF and&#xD;
           non-VEGF angiogenic factors and clinical efficacy of this drug, as measured by response,&#xD;
           duration of response, and time to progression in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive oral sunitinib malate once daily for 8 weeks. Within 2 weeks after&#xD;
      completion of neoadjuvant chemotherapy, patients undergo a nephrectomy and evaluation for&#xD;
      response to therapy. Beginning 4-8 weeks after surgery patients resume oral sunitinib malate&#xD;
      once daily for up to 12 months in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients with disease progression after 8 weeks of adjuvant treatment receive treatment off&#xD;
      study with other agents.&#xD;
&#xD;
      Viable (non-necrotic) tumor and non-tumor kidney tissue samples are obtained at the time of&#xD;
      nephrectomy for correlative biomarker studies. Tissue samples are analyzed for gene&#xD;
      expression of VEGF and non-VEGF angiogenic factors by real-time RT-PCR, western blot, and/or&#xD;
      IHC. Blood samples are obtained at baseline and at 4 and 8 weeks for evaluation of&#xD;
      circulating levels of VEGF and selected chemokines.&#xD;
&#xD;
      After completion of study therapy, patients are followed monthly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated early due to low accrual.&#xD;
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Describe the gene expression of VEGF and non-VEGF from eligible patients being treatment with Sunitinib.</measure>
    <time_frame>at various points throughout the study duration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe the association between quantitative gene expression levels of VEGF and non-VEGF angiogenic factors with the clinical efficacy of Sunitinib as measured by response, duration or response and time to progression</measure>
    <time_frame>at various points throughout the study duration</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib will be administered for 8 weeks prior to sugery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of clear cell renal cell carcinoma&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  Primary tumor is considered amenable to surgery&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1&#xD;
             dimension (longest diameter to be recorded) as &gt; 20 mm by conventional techniques or&#xD;
             as &gt; 10 mm by spiral CT scan&#xD;
&#xD;
          -  No untreated brain metastases&#xD;
&#xD;
               -  Treated brain metastases allowed provided lesion has been stable on two&#xD;
                  consecutive CT or MRI scans separated by ≥ 2 months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Leukocytes ≥ 3,000/μL&#xD;
&#xD;
          -  ANC ≥ 1,500/μL&#xD;
&#xD;
          -  Platelet count ≥ 75,000/μL&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
          -  Total Bilirubin ≤ 2 times upper limits of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 2.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to undergo nephrectomy and treatment with sunitinib malate&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to sunitinib malate&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior systemic treatment with sunitinib malate&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  Concurrent medications or substances known to affect, or with the potential to affect,&#xD;
             the activity or pharmacokinetics of sunitinib malate allowed at the discretion of the&#xD;
             principal investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry A. Drabkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>September 4, 2008</study_first_submitted>
  <study_first_submitted_qc>September 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2008</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Harry Drabkin</investigator_full_name>
    <investigator_title>Director, Hematology Oncology Division</investigator_title>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

